Triterpene saponins from Barringtonia acutangula (L.) Gaertn as a potent inhibitor of 11β-HSD1 for type 2 diabetes mellitus, obesity, and metabolic syndrome
Open Access
- 2 September 2020
- journal article
- research article
- Published by Springer Nature in Clinical Phytoscience
- Vol. 6 (1), 1-5
- https://doi.org/10.1186/s40816-020-00210-y
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Metabolic syndrome: pathophysiology, management, and modulation by natural compoundsTherapeutic Advances in Cardiovascular Disease, 2017
- Structure Identification and Anti-Cancer Pharmacological Prediction of Triterpenes from Ganoderma lucidumMolecules, 2016
- BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacologyNucleic Acids Research, 2015
- 11β‐Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2012
- Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatmentDiabetology & Metabolic Syndrome, 2010
- Selective inhibition of 11β-hydroxysteroid dehydrogenase 1 by 18α-glycyrrhetinic acid but not 18β-glycyrrhetinic acidThe Journal of Steroid Biochemistry and Molecular Biology, 2009
- A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesisJournal of Endocrinology, 2008
- Conformational Flexibility in Crystal Structures of Human 11β-Hydroxysteroid Dehydrogenase Type I Provide Insights into Glucocorticoid Interconversion and Enzyme RegulationJournal of Biological Chemistry, 2005
- Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic miceProceedings of the National Academy of Sciences, 2004
- Saponins from Barringtonia acutangulaPhytochemistry, 1994